We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+13.51%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.22B
AUM Growth
+$345M
(+18%)
Cap. Flow
-$140M
Cap. Flow
% of AUM
-6.29%
Top 10 Holdings %
Top 10 Hldgs %
38.04%
Holding
103
New
16
Increased
23
Reduced
25
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DexCom
DXCM
|
+$82.9M |
| 2 |
McKesson
MCK
|
+$64.6M |
| 3 |
Glaukos
GKOS
|
+$62M |
| 4 |
Viatris
VTRS
|
+$60.6M |
| 5 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$34.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$68.6M |
| 2 |
Gilead Sciences
GILD
|
+$66.4M |
| 3 |
NXTM
NxStage Medical Inc.
NXTM
|
+$60.1M |
| 4 |
NVRO
NEVRO CORP.
NVRO
|
+$28M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$26.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 76.21% |
| 2 | Financials | 0.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SEM
26
DELISTED
Select Medical
SEM
| $22.9M | 1.03% |
2,217,194
+1,280,597
| +137% | +$11.8M |
|
|
PDCO
27
DELISTED
Patterson Companies, Inc.
PDCO
| $21.9M | 0.99% |
566,000
+172,738
| +44% | +$6.9M |
|
|
SYRS
28
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $18.7M | 0.84% |
126,895
| – | – |
|
29
Molina Healthcare
MOH
$11.8B
| $17.7M | 0.8% |
258,000
+106,335
| +70% | +$6.92M |
|
30
Cartesian Therapeutics
RNAC
$243M
| $17.4M | 0.78% |
31,721
-3,612
| -10% | -$1.92M |
|
|
AAC
31
DELISTED
AAC Holdings
AAC
| $17.2M | 0.78% |
1,733,276
-242,071
| -12% | -$2.07M |
|
|
SCTL
32
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
| $17.1M | 0.77% |
2,120,379
| – | – |
|
|
SYBX
33
DELISTED
Synlogic
SYBX
| $16.2M | 0.73% |
+56,676
| New | +$11.6M |
|
|
PTLA
34
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $16.1M | 0.73% |
298,545
-120,455
| -29% | -$7.07M |
|
35
eHealth
EHTH
$46M
| $16.1M | 0.72% |
672,994
-17,354
| -3% | -$353K |
|
|
OXFD
36
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $15.9M | 0.72% |
945,710
| – | – |
|
|
LOXO
37
DELISTED
Loxo Oncology, Inc
LOXO
| $15.6M | 0.7% |
169,000
-82,167
| -33% | -$6.38M |
|
38
Ardelyx
ARDX
$1.29B
| $15.4M | 0.69% |
2,746,480
+466,700
| +20% | +$2.46M |
|
|
AAAP
39
DELISTED
Advanced Accelerator Applications S.A.
AAAP
| $14.7M | 0.66% |
218,000
-174,904
| -45% | -$8.49M |
|
|
NEOS
40
DELISTED
Neos Therapeutics, Inc
NEOS
| $14.4M | 0.65% |
1,568,921
+109,726
| +8% | +$834K |
|
|
BPMC
41
DELISTED
Blueprint Medicines
BPMC
| $14.1M | 0.64% |
203,000
| – | – |
|
42
Agios Pharmaceuticals
AGIO
$2.39B
| $13.9M | 0.63% |
+208,000
| New | +$12.5M |
|
43
CytomX Therapeutics
CTMX
$795M
| $13.8M | 0.62% |
756,822
| – | – |
|
|
EPZM
44
DELISTED
Epizyme, Inc
EPZM
| $13.3M | 0.6% |
700,526
+38,157
| +6% | +$582K |
|
|
LKFT
45
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.91B
| $13.2M | 0.6% |
130,000
-57,501
| -31% | -$5.02M |
|
46
Wave Life Sciences
WVE
$1.13B
| $12.6M | 0.57% |
580,000
-166,841
| -22% | -$3.35M |
|
47
Xencor
XNCR
$1.42B
| $12M | 0.54% |
522,000
-40,236
| -7% | -$893K |
|
48
argenx
ARGX
$53.7B
| $11.5M | 0.52% |
509,022
| – | – |
|
|
ALPN
49
DELISTED
Alpine Immune Sciences Inc
ALPN
| $10.8M | 0.49% |
933,100
-3
| -0% | -$28 |
|
|
IVTY
50
DELISTED
Invuity, Inc
IVTY
| $10.5M | 0.47% |
1,177,229
| – | – |
|
Similar funds
FT
GRQ
PCM
VA
QC
IC
NW
AAF
Deerfield Management's Q3 2017 Portfolio in Review
As of Q3 2017, Deerfield Management held 103 positions worth $2.22B, up 18% from $1.87B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Deerfield Management withdrew a net $140M in Q3 2017, closing 12 positions and reducing 25 holdings. Its most notable exit was Gilead Sciences, an estimated $66.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 76% of assets, up from 72% a quarter earlier, followed by Financials.
Against the trend, Deerfield Management opened a new position in Insulet worth $27.4M.
- Deerfield Management's largest Q3 2017 buy was Insulet: 497,000 shares worth $27.4M.
- Deerfield Management added most to DexCom in Q3 2017, an estimated $82.9M increase.
- Deerfield Management's biggest Q3 2017 reduction was AveXis, Inc. Common Stock, cutting an estimated $68.6M.
- Deerfield Management fully exited Gilead Sciences in Q3 2017, selling an estimated $66.4M.
- Deerfield Management's ten largest holdings make up 38% of its $2.22B portfolio in Q3 2017.
- Deerfield Management opened 16 new positions and closed 12 in Q3 2017.
- Deerfield Management's portfolio value rose 18% quarter-over-quarter to $2.22B.
Based on Deerfield Management's 13F filing for Q3 2017, filed 13 Nov 2017.